Pulmozyme and Multi-therapy Approach

Pulmozyme is often a component of a Multi-therapy Approach in the management of cystic fibrosis 15-19

Every prescribed therapy plays an important role in managing the destructive cycle of cystic fibrosis by targeting different disease mechanisms 15-19

A multi-therapy approach targets different disease mechanisms 


NOTE: In several pivotal phase 3 trials assessing the efficacy and safety of CFTR modulators, patients continued to receive their Pulmozyme treatment15-19

Controlling mucus is an essential component in the management of cystic fibrosis 7

3. Harms  HK et al. Dnase International Study Group. Multicenter, open-label study of recombinant human Dnase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998; 23(3): 155-161; 

4. King, M. Mucolytics and mucus clearance. In Rubin BK, van der Sxhans CP, eds. Therapy for Mucus-Clearance Disorders. New Yoirk, NY: Marcel Dekker Inc, 2004:201-224; 

5. Chmiel, JF, Kanstan MW. Anti-inflammatory medication for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005; 4(4):255-273; 

6. Puchelle E et al. Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration. 1995; 62(suppl 1) 2-12;

7. Lyczak, JB et al. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2—2; 15(2):194-222.

15. Orkambi summary of product characteristics. Vertex Pharmaceuticals (Europe) Ltd.

16. Wainwright CE et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-231.

17. Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.

18. Davies JC. Et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219-1225.

19. Kalydeco summary of product characteristics. Vertex Pharmaceuticals (Europe) Ltd.

20. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2015. https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report. Accessed April 3, 2017.

21. Clancy JP. Ongoing research into CFTR modulation. Adv Stud Med. 2010;10(1):14-18.

22. Bennet, WD et al. Hydrator therapies for chronic bronchitis: lessons from cystic fibrosis. Ann Am Thorac Soc. 2016;13(2):S186-S190.

Video:  Cystic Fibrosis Foundation. Treatment and Therapies. https://www.cff.org/Life-with-CF/Treatments-and-Therapies/